Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 12/20 | 0.72 |
| ▸ | ABL1 | P00519 | 2/20 | 0.72 |
| ▸ | BCR | P11274 | 2/20 | 0.72 |
| ▸ | MAP2K1 | Q02750 | 7/20 | 0.70 |
| ▸ | FYN | P06241 | 1/20 | 0.70 |
| ▸ | EGFR | P00533 | 1/20 | 0.69 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.69 |
| ▸ | RAF1 | P04049 | 1/20 | 0.65 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6684408 | 0.91 | SRC (0.76) | SRCABL1BCRMAP2K1FYN | |
| SCHEMBL6832310 | 0.86 | SRC (0.74) | SRCABL1BCRMAP2K1FYN | |
| SCHEMBL6834093 | 0.86 | SRC (0.57) | SRCABL1BCREGFRERBB2 | |
| SCHEMBL6685924 | 0.85 | SRC (0.83) | SRCABL1BCRMAP2K1FYN | |
| SCHEMBL6930676 | 0.84 | SRC (0.57) | SRCABL1BCREGFRERBB2 | |
| SCHEMBL5201099 | 0.82 | SRC (1.00) | SRCABL1BCRMAP2K1FYN | |
| SCHEMBL4485027 | 0.82 | SRC (0.71) | SRCABL1BCRMAP2K1FYN | |
| SCHEMBL6383141 | 0.81 | EGFR (1.00) | SRCABL1BCRMAP2K1FYN | |
| SCHEMBL6382257 | 0.81 | SRC (0.76) | SRCABL1BCRMAP2K1FYN | |
| SCHEMBL6381057 | 0.81 | SRC (0.76) | SRCABL1BCRMAP2K1FYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2004108703-A1 | PYRAZINYL 3-CYANOQUINOLINE DERIVATIVES FOR USE IN THE TREATMENT OF TUMOURS | ASTRAZENECA AB (SE) | 2004-12-16 | — | — | WO | disclosed |